@article{d5869481563c4d0bbe3402263baea7a3,
title = "A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose",
abstract = "Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.",
keywords = "Cytomegalovirus, Disseminating, Durable, Ebola, Ebolavirus, Great apes, Mouse, Protection, Vaccine",
author = "Yoshimi Tsuda and Parkins, {Christopher J.} and Patrizia Caposio and Friederike Feldmann and Sara Botto and Susan Ball and Ilhem Messaoudi and Luka Cicin-Sain and Heinz Feldmann and Jarvis, {Michael A.}",
note = "Funding Information: We thank Dr U. Koszinowski (Max von Pettenkofer-Institute, Ludwig-Maximilians-University, Germany) for providing the pSMfr3 MCMV BAC, and Dr D. Court (NCI-Frederick, MD) for providing the lambda-based recombination system used to construct the original MCMV/ZEBOV-NP CTL construct. We appreciate K. Marshall (VGTI, OR) and J. Bailey (NIAID, MT) for their organization and coordination of animals used in the study. We also thank the members of Rocky Mountain Veterinary Branch (DIR, NIAID, NIH) for assistance with animal care. Finally, we thank Drs H. Ebihara (DIR, NIAID, NIH), A. Marzi (DIR, NIAID, NIH), P. Barry (University of California at Davis, CA), M. Cranfield (Mountain Gorilla Veterinary Project, Baltimore, MD) for insightful discussions. This study was supported by R21 (AI088442) and the Intramural Research Program of the NIAID, NIH; and University of Plymouth, School of Biomedical and Healthcare Sciences internal funding. Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd.",
year = "2015",
doi = "10.1016/j.vaccine.2015.03.029",
language = "English (US)",
volume = "33",
pages = "2261--2266",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "19",
}